Proscia: Findings illustrate promise of technology to lower misdiagnosis rate for deadliest form of skin cancer PHILADELPHIA – November 1, 2022 – Proscia®, a leading provider of digital and computational pathology solutions, has released...

Findings of multi-site study highlight potential of technology in real-world practice PHILADELPHIA – October 5, 2021 – Proscia®, a leading provider of digital and computational pathology solutions, has released study results on new...

NEW YORK – Artificial intelligence company Nucleai and Jefferson Health on Tuesday announced a collaboration to discover histological biomarkers that predict response to immunotherapy. Tel Aviv-based Nucleai will use its ATOM platform to...